# Safety and Pharmacokinetics Study of SyB C-1101 in Patients With Recurrent/Relapsed or Refractory Myelodysplastic Syndrome (MDS)

> **NCT02014051** · PHASE1 · COMPLETED · sponsor: **SymBio Pharmaceuticals** · enrollment: 10 (actual)

## Conditions studied

- Myelodysplastic Syndrome

## Interventions

- **DRUG:** SyB C-1101

## Key facts

- **NCT ID:** NCT02014051
- **Lead sponsor:** SymBio Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-03
- **Primary completion:** 2014-11
- **Final completion:** 2014-11
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2022-11-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02014051

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02014051, "Safety and Pharmacokinetics Study of SyB C-1101 in Patients With Recurrent/Relapsed or Refractory Myelodysplastic Syndrome (MDS)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02014051. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*